Product Description
Gadoversetamide is a paramagnetic extracellular magnetic resonance imaging (MRI) contrast agent that facilitates visualization of abnormal vascularity. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Gadoversetamide)
Mechanisms of Action: Contrast Agent
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Brazil | Canada | Chile | Colombia | Denmark | European Medicines Agency | Germany | Hungary | India | Ireland | Italy | Latvia | Lithuania | Peru | Portugal | Russia | Slovenia | South Africa | Spain | Sweden | Taiwan | Thailand | Turkey
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/17/2022 |
News Article |
LifeSci Special Opportunities Responds to Recent Press Release Issued by Diffusion Pharmaceuticals |
|
04/15/2020 |
News Article |
Global Acousto-optic Devices Industry |
|
04/14/2020 |
News Article |
Global Acousto-optic Devices Industry |